Business
NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™
About this update from Neuroone Medical Technologies Corporation
[{"type":"text","content":"ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system EDEN PRAIRIE, Minn., June 20, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved and granted a new ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) code for the OneRF™ Ablation procedure. The new code is 00503Z4 Destruction of Brain Using Stereoelectroencephalographic Radiofrequency Ablation, Percutaneous Approach. This code allows hospital reporting of inpatient procedures that are performed using the OneRF™ Ablation system, which has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures. ICD-10-PCS codes play a critical role in the healthcare system, ensuring efficient and accurate documentation, billing, and analysis. The code goes into effect beginning October 1, 2024. “We are pleased that CMS has provided an ICD-10-PCS code that describes our OneRF procedure, which we believe will drive better recognition of our technology and greater utilization within the healthcare system,” said Dave Rosa, CEO of NeuroOne. “In our view, CMS approval of our new code is a critical step in facilitating broader market acceptance of our technology’s potential to reduce hospital stays, numbers of surgeries, and adverse events, while offering enhanced patient safety.” The OneRF™ Ablation System is NeuroOne’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. In addition to the OneRF™ Ablation System, NeuroOne’s other FDA-cleared devices include the Evo® cortical and sEEG electrode product lines which are used primarily for stimulation, recording and monitoring of electrical activity in the brain fo...